Compare · DXCM vs HTFL
DXCM vs HTFL
Side-by-side comparison of DexCom Inc. (DXCM) and Heartflow Inc. (HTFL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and HTFL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 7.5x HTFL ($4.43B).
- Over the past year, DXCM is up 29.2% and HTFL is up 42.5% - HTFL leads by 13.3 points.
- DXCM has been more active in the news (6 items in the past 4 weeks vs 2 for HTFL).
- DXCM has more recent analyst coverage (25 ratings vs 9 for HTFL).
- Company
- DexCom Inc.
- Heartflow Inc.
- Price
- $86.05-1.93%
- $48.23-5.21%
- Market cap
- $33.10B
- $4.43B
- 1M return
- -2.13%
- -2.71%
- 1Y return
- +29.24%
- +42.52%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2025
- News (4w)
- 6
- 2
- Recent ratings
- 25
- 9
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest HTFL
- SEC Form 4 filed by Heartflow Inc.
- Chief Medical Officer Rogers Campbell exercised 13,179 shares at a strike of $7.94 and sold $987,052 worth of shares (19,682 units at $50.15) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 79,956 units (SEC Form 4)
- Chief Financial Officer Verghese Vikram sold $1,230,742 worth of Common Stock. (24,345 units at $50.55) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 155,183 units (SEC Form 4)
- Chief Financial Officer Verghese Vikram sold $1,751,611 worth of Common Stock. (34,975 units at $50.08) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 179,528 units (SEC Form 4)
- Chief Executive Officer Farquhar John C.M. sold $1,819,605 worth of shares (38,900 units at $46.78) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 321,914 units (SEC Form 4)
- Chief Financial Officer Verghese Vikram sold $332,212 worth of Common Stock. (6,640 units at $50.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 214,503 units (SEC Form 4)
- UBS resumed coverage on Heartflow with a new price target
- Chief Financial Officer Verghese Vikram sold $1,665,796 worth of Common Stock. (33,416 units at $49.85) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 221,143 units (SEC Form 4)
- Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half
- Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference